一分钟看懂
这是一项关于血液系统恶性肿瘤的II 期研究，登记的药物或干预包括Talquetamab，当前状态为招募中。登记地点显示中国北京、广州、杭州、苏州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Talquetamab · II 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出5项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出4项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University Third Hospital · 北京
- Sun Yat Sen University Cancer Center · 广州
- The 1st Affiliated Hospital Of Medical College Zhejiang University 1 · 杭州
- The 1St Affiliated Hospital of Medical College Zhejiang University · 杭州
- First Affiliated Hospital SooChow University · 苏州
- Institute of Hematology & Blood Disease Hospital Chinese Academy of Medical Science · 天津
- The Second Affiliated Hospital of Xi'an Jiaotong University · 西安
- The First Affiliated Hospital of Xian Jiaotong University · 西安
公开的入选条件
- * Documented initial diagnosis of multiple myeloma according to international myeloma working group (IMWG) diagnostic criteria
- * Part 3: Measurable disease cohort A, cohort B, cohort C and cohort D: multiple myeloma must be measurable by central laboratory assessment; Cohort E: Multiple myeloma must be measurable by local laboratory assessment
- * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
- * Women of childbearing potential must have a negative pregnancy test at screening and prior to the first dose of study drug using a highly sensitive pregnancy test either serum (beta human chorionic gonadotropin \[hCG\]) or urine
- * Willing and able to adhere to the prohibitions and restrictions specified in this protocol
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04634552；登记信息更新于 2026-09-25。